Celadon Pharmaceuticals PLC (GB:CEL) has released an update.
Celadon Pharmaceuticals PLC, a UK-based pioneer in cannabis-based medicines, has announced the upcoming trading of 238,095 new ordinary shares on the AIM market on June 11, 2024, with additional shares to follow in July and August. This move is part of the company’s strategy to expand its share capital, which will total 65,982,712 ordinary shares with corresponding voting rights. Celadon, known for its EU-GMP approved 100,000 sq. ft facility and a Home Office license for commercial supply, is actively involved in clinical trials for chronic pain and holds a stake in Kingdom Therapeutics, which focuses on cannabinoid medicine for autism.
For further insights into GB:CEL stock, check out TipRanks’ Stock Analysis page.
